my country's first original ADC new drug Rongchang Biological Vidicuzumab is planned to be included in breakthrough therapy

On June 21, CDE announced that the new indication of Rongchang Bio-Vidi Cetuzumab will be included in a breakthrough treatment product for HER2-positive advanced breasts with liver metastases that have been treated with trastuzumab and taxanes in the past.

Vedicitumumab is an antibody-conjugated drug that contains the human epidermal growth factor receptor-2 (HER2) antibody portion, linker and the cytotoxic drug monomethyl auristatin E (MMAE)

At the beginning of June 2021, at the ASCO annual meeting, the clinical data of vedicitumumab was announced

At present, the indications of vedicitumumab for urothelial cancer have been recognized as a breakthrough therapy in China and the United States.

Data source: Insight database

In the future, Rongchang Bioplans to carry out phase II/III clinical studies for multiple indications in 2021, involving tumor fields such as breast cancer, gastric cancer, NSCLC, and cholangiocarcinoma